Direct promoter induction of p19Arf by Pit-1 explains the dependence receptor RET/Pit-1/p53-induced apoptosis in the pituitary somatotroph cells

Oncogene

Volumn 31, Issue 23, 2012, Pages 2824-2835

  Diaz Rodriguez, E ^a   Garcia Lavandeira M ^a   Perez Romero, S ^a   Senra, A ^a   Canibano C ^a,d   Palmero, I ^b   Borrello, M G ^c   Dieguez, C ^a   Alvarez, C V ^a,d  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d Ibiomed   (Spain)

Author keywords

apoptosis; dependence receptor; OIA; p19Arf; p53; Pit 1

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA BINDING PROTEIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MESSENGER RNA; PROTEIN P19; PROTEIN P53; PROTEIN RET; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR PIT 1;

ACROMEGALY; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE EXPRESSION; GENE LOCUS; GROWTH HORMONE SECRETING CELL; HUMAN; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; MALE; METABOLIC DISORDER; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROCESSING; RAT;

ANIMALS; APOPTOSIS; CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-RET; RATS; REGULATORY SEQUENCES, NUCLEIC ACID; RNA, SMALL INTERFERING; SOMATOTROPHS; TRANSCRIPTION FACTOR PIT-1; TUMOR SUPPRESSOR PROTEIN P53;

RODENTIA;

EID: 84861981502     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.458     Document Type: Article

References (62)

1. Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL et al. (1998). p14ARF links the tumour suppressors RB and p53. Nature 395: 124-125. (Pubitemid 28425642)
2. Bordeaux MC, Forcet C, Granger L, Corset V, Bidaud C, Billaud M et al. (2000). The RET proto-oncogene induces apoptosis: a novel mechanism for hirschsprung disease. EMBO J 19: 4056-4063. (Pubitemid 30608544)
3. Bravo SB, Garcia-Rendueles ME, Perez-Romero S, Cameselle-Teijeiro J, Rodrigues JS, Barreiro F et al. (2010). Expression of exogenous proteins and short hairpin RNAs in human primary thyrocytes. Anal Biochem 400: 219-228.
4. Bravo SB, Pampin S, Cameselle-Teijeiro J, Carneiro C, Dominguez F, Barreiro F et al. (2003). TGF-beta-induced apoptosis in human thyrocytes is mediated by p27kip1 reduction and is overridden in neoplastic thyrocytes by NF-kappaB activation. Oncogene 22: 7819-7830. (Pubitemid 37485541)
5. Canibano C, Rodriguez NL, Saez C, Tovar S, Garcia-Lavandeira M, Borrello MG et al. (2007). The dependence receptor ret induces apoptosis in somatotrophs through a pit-1/p53 pathway, preventing tumor growth. EMBO J 26: 2015-2028. (Pubitemid 46625783)
6. Carneiro C, Alvarez CV, Zalvide J, Vidal A, Dominguez F. (1998). TGF-beta1 actions on FRTL-5 cells provide a model for the physiological regulation of thyroid growth. Oncogene 16: 1455-1465. (Pubitemid 28151852)
7. Castrillo JL, Theill LE, Karin M. (1991). Function of the homeodomain protein GHF1 in pituitary cell proliferation. Science 253: 197-199. (Pubitemid 21917141)
8. Chen D, Shan J, Zhu WG, Qin J, Gu W. (2010). Transcriptionindependent ARF regulation in oncogenic stress-mediated p53 responses. Nature 464: 624-627.
9. Chesnokova V, Kovacs K, Castro AV, Zonis S, Melmed S. (2005). Pituitary hypoplasia in pttg-/-mice is protective for rb +-pituitary tumorigenesis. Mol Endocrinol 19: 2371-2379. (Pubitemid 41252829)
10. Chesnokova V, Yu R, Ben-Shlomo A, Shlomo M. (2008a) In: Melmed S, Rochefort H, Chanson P, Christen Y (eds). Hormonal Control of Cell Cycle. Springer: Berlin Heidelberg, pp 83-87.
11. Chesnokova V, Zonis S, Kovacs K, Ben-Shlomo A, Wawrowsky K, Bannykh S et al. (2008b). p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci USA 105: 17498-17503.
12. Chesnokova V, Zonis S, Rubinek T, Yu R, Ben-Shlomo A, Kovacs K et al. (2007). Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res 67: 10564-10572. (Pubitemid 350070833)
13. Clayton PE, Banerjee I, Murray PG, Renehan AG. (2011). Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol 7: 11-24.
14. Colao A, Ochoa AS, Auriemma RS, Faggiano A, Pivonello R, Lombardi G. (2010). Pituitary carcinomas. Front Horm Res 38: 94-108.
15. Coya R, Alvarez CV, Perez F, Gianzo C, Dieguez C. (1999). Effects of TGF-beta1 on prolactin synthesis and secretion: an in-vitro study. J Neuroendocrinol 11: 351-360. (Pubitemid 29199693)
16. Cunnington MS, Santibanez Koref M, Mayosi BM, Burn J, Keavney B. (2010). Chromosome 9p21 SNPs associated with multiple disease phenotypes correlate with ANRIL expression. PLoS Genet 6: e1000899.
17. Davis SW, Castinetti F, Carvalho LR, Ellsworth BS, Potok MA, Lyons RH et al. (2010). Molecular mechanisms of pituitary organogenesis: in search of novel regulatory genes. Mol Cell Endocrinol 323: 4-19.
18. del Arroyo AG, El Messaoudi S, Clark PA, James M, Stott F, Bracken A et al. (2007). E2F-dependent induction of p14ARF during cell cycle re-entry in human T cells. Cell Cycle 6: 2697-2705. (Pubitemid 350224054)
19. de Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV et al. (1998). E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev 12: 2434-2442. (Pubitemid 28371362)
20. Evan GI, d'Adda di Fagagna F. (2009). Cellular senescence: hot or what? Curr Opin Genet Dev 19: 25-31.
21. Garcia A, Alvarez CV, Smith RG, Dieguez C. (2001). Regulation of pit-1 expression by ghrelin and GHRP-6 through the GH secretagogue receptor. Mol Endocrinol 15: 1484-1495. (Pubitemid 32826401)
22. Garcia-Lavandeira M, Diaz-Rodriguez E, Garcia-Rendueles ME, Rodrigues JS, Perez-Romero S, Bravo SB et al. (2010). Functional role of the RET dependence receptor, GFRa co-receptors and ligands in the pituitary. Front Horm Res 38: 127-138.
23. Garcia-Lavandeira M, Quereda V, Flores I, Saez C, Diaz-Rodriguez E, Japon MA et al. (2009). A GRFa2/Prop1/stem (GPS) cell niche in the pituitary. PLoS ONE 4: e4815.
24. Gil J, Peters G. (2006). Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol 7: 667-677. (Pubitemid 44268212)
25. Goldschneider D, Mehlen P. (2010). Dependence receptors: a new paradigm in cell signaling and cancer therapy. Oncogene 29: 1865-1882.
26. Guenebeaud C, Goldschneider D, Castets M, Guix C, Chazot G, Delloye-Bourgeois C et al. (2010). The dependence receptor UNC5H2/B triggers apoptosis via PP2A-mediated dephosphorylation of DAP kinase. Mol Cell 40: 863-876.
27. Harris SL, Levine AJ. (2005). The p53 pathway: positive and negative feedback loops. Oncogene 24: 2899-2908. (Pubitemid 40638098)
28. Herman V, Drazin NZ, Gonsky R, Melmed S. (1993). Molecular screening of pituitary adenomas for gene mutations and rearrangements. J Clin Endocrinol Metab 77: 50-55. (Pubitemid 23206775)
29. Inoue K, Roussel MF, Sherr CJ. (1999). Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc Natl Acad Sci USA 96: 3993-3998. (Pubitemid 29169024)
30. Itahana K, Zhang Y. (2008). Mitochondrial p32 is a critical mediator of ARF-induced apoptosis. Cancer Cell 13: 542-553. (Pubitemid 351763900)
31. Japon MA, Rubinstein M, Low MJ. (1994). In situ hybridization analysis of anterior pituitary hormone gene expression during fetal mouse development. J Histochem Cytochem 42: 1117-1125. (Pubitemid 24226339)
32. Japon MA, Urbano AG, Saez C, Segura DI, Cerro AL, Dieguez C et al. (2002). Glial-derived neurotropic factor and RET gene expression in normal human anterior pituitary cell types and in pituitary tumors. J Clin Endocrinol Metab 87: 1879-1884. (Pubitemid 34615283)
33. Junttila MR, Evan GI. (2009). p53-a jack of all trades but master of none. Nat Rev Cancer 9: 821-829.
34. Khutornenko AA, Roudko VV, Chernyak BV, Vartapetian AB, Chumakov PM, Evstafieva AG. (2010). Pyrimidine biosynthesis links mitochondrial respiration to the p53 pathway. Proc Natl Acad Sci USA 107: 12828-12833.
35. Kirsch M, Morz M, Pinzer T, Schackert HK, Schackert G. (2009). Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas. Genes Chromosomes Cancer 48: 143-154.
36. Kovi RC, Paliwal S, Pande S, Grossman SR. (2010). An ARF/CtBP2 complex regulates BH3-only gene expression and p53-independent apoptosis. Cell Death Differ 17: 513-521.
37. Kuo ML, den Besten W, Bertwistle D, Roussel MF, Sherr CJ. (2004). N-terminal polyubiquitination and degradation of the arf tumor suppressor. Genes Dev 18: 1862-1874. (Pubitemid 39025096)
38. Leontieva OV, Gudkov AV, Blagosklonny MV. (2010). Weak p53 permits senescence during cell cycle arrest. Cell Cycle 9: 4323-4327.
39. Lin SC, Lin CR, Gukovsky I, Lusis AJ, Sawchenko PE, Rosenfeld MG. (1993). Molecular basis of the little mouse phenotype and implications for cell type-specific growth. Nature 364: 208-213. (Pubitemid 23257078)
40. Meek DW. (2009). Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 9: 714-723.
41. Melmed S. (2003). Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 112: 1603-1618. (Pubitemid 38063716)
42. Moll UM, Wolff S, Speidel D, Deppert W. (2005). Transcriptionindependent pro-apoptotic functions of p53. Curr Opin Cell Biol 17: 631-636.
43. Nikoletopoulou V, Lickert H, Frade JM, Rencurel C, Giallonardo P, Zhang L et al. (2010). Neurotrophin receptors TrkA and TrkC cause neuronal death whereas TrkB does not. Nature 467: 59-63.
44. Palmero I, Pantoja C, Serrano M. (1998). p19ARF links the tumour suppressor p53 to ras. Nature 395: 125-126. (Pubitemid 28425643)
45. Pasmant E, Laurendeau I, Heron D, Vidaud M, Vidaud D, Bieche I. (2007). Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res 67: 3963-3969. (Pubitemid 46762186)
46. Pfaffle RW, DiMattia GE, Parks JS, Brown MR, Wit JM, Jansen M et al. (1992). Mutation of the POU-specific domain of pit-1 and hypopituitarism without pituitary hypoplasia. Science 257: 1118-1121.
47. Raveh T, Droguett G, Horwitz MS, DePinho RA, Kimchi A. (2001). DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat Cell Biol 3: 1-7. (Pubitemid 32114825)
48. Robertson KD, Jones PA. (1998). The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol 18: 6457-6473. (Pubitemid 28500536)
49. Serrano M. (2010). Shifting senescence into quiescence by turning up p53. Cell Cycle 9: 4256-4257.
50. Solloso A, Barreiro L, Seoane R, Nogueira E, Canibano C, Alvarez CV et al. (2008). GHRH proliferative action on somatotrophs is cell-type specific and dependent on pit-1/GHF-1 expression. J Cell Physiol 215: 140-150. (Pubitemid 351363199)
51. Taneja P, Maglic D, Kai F, Sugiyama T, Kendig RD, Frazier DP et al. (2010). Critical roles of DMP1 in human epidermal growth factor receptor 2/neu-arf-p53 signaling and breast cancer development. Cancer Res 70: 9084-9094.
52. Tanikawa C, Matsuda K, Fukuda S, Nakamura Y, Arakawa H. (2003). p53RDL1 regulates p53-dependent apoptosis. Nat Cell Biol 5: 216-223. (Pubitemid 36322248)
53. Tsai KY, MacPherson D, Rubinson DA, Nikitin AY, Bronson R, Mercer KL et al. (2002). ARF mutation accelerates pituitary tumor development in rb +-mice. Proc Natl Acad Sci USA 99: 16865-16870. (Pubitemid 36034064)
54. Urbano AG, Suarez-Penaranda JM, Dieguez C, Alvarez CV. (2000). GDNF and RET-gene expression in anterior pituitary-cell types. Endocrinology 141: 1893-1896. (Pubitemid 32274419)
55. van Beek AP, Wolffenbuttel BH, Runge E, Trainer PJ, Jonsson PJ, Koltowska-Haggstrom M. (2010). The pituitary gland and agedependent regulation of body composition. J Clin Endocrinol Metab 95: 3664-3674.
56. Vousden KH. (2000). P53: death star. Cell 103: 691-694.
57. Wang H, Ozaki T, Shamim Hossain M, Nakamura Y, Kamijo T, Xue X et al. (2008). A newly identified dependence receptor UNC5H4 is induced during DNA damage-mediated apoptosis and transcriptional target of tumor suppressor p53. Biochem Biophys Res Commun 370: 594-598.
58. Ward RD, Stone BM, Raetzman LT, Camper SA. (2006). Cell proliferation and vascularization in mouse models of pituitary hormone deficiency. Mol Endocrinol 20: 1378-1390. (Pubitemid 43801238)
59. Yap KL, Li S, Munoz-Cabello AM, Raguz S, Zeng L, Mujtaba S et al. (2010). Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 38: 662-674.
60. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD et al. (1999). Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 84: 761-767. (Pubitemid 29075718)
61. Zhou Z, Flesken-Nikitin A, Levine CG, Shmidt EN, Eng JP, Nikitina EY et al. (2005). Suppression of melanotroph carcinogenesis leads to accelerated progression of pituitary anterior lobe tumors and medullary thyroid carcinomas in rb +-mice. Cancer Res 65: 787-796. (Pubitemid 40216436)
62. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ et al. (1998). Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12: 2424-2433. (Pubitemid 28371361)